| 1 | THENAPPAN T, ORMISTON M L, RYAN J J, et al.. Pulmonary arterial hypertension: pathogenesis and clinical management[J/OL]. BMJ, 2018, 360: j5492[2023-06-26]. . | 
																													
																							| 2 | SIMONNEAU G, MONTANI D, CELERMAJER D S, et al.. Haemodynamic definitions and updated clinical classification of pulmonary hypertension[J/OL]. Eur. Respir. J., 2019, 53(1): 1801913[2022-11-03]. . | 
																													
																							| 3 | XIAO Y, CHEN P P, ZHOU R L, et al.. Pathological mechanisms and potential therapeutic targets of pulmonary arterial hypertension: a review[J]. Aging Dis., 2020, 11(6): 1623-1639. | 
																													
																							| 4 | ZELT J G E, SUGARMAN J, WEATHERALD J, et al.. Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era[J/OL]. Pulm. Circ., 2022, 59(6): 2101552[2022-10-07]. . | 
																													
																							| 5 | MEHRA R, TJURMINA O A, AJIJOLA O A, et al.. Research opportunities in autonomic neural mechanisms of cardiopulmonary regulation: a report from the national heart, lung, and blood institute and the national institutes of health office of the director workshop[J]. JACC Basic Transl. Sci., 2022, 7(3): 265-293. | 
																													
																							| 6 | VAILLANCOURT M, CHIA P, SARJI S, et al.. Autonomic nervous system involvement in pulmonary arterial hypertension[J/OL]. Eur. Respir. J., 2017, 18(1): 201[2023-06-06]. . | 
																													
																							| 7 | KARPOV A A, VACHRUSHEV N S, SHILENKO L A, et al.. Sympathetic denervation and pharmacological stimulation of parasympathetic nervous system prevent pulmonary vascular bed remodeling in rat model of chronic thromboembolic pulmonary hypertension[J/OL]. J. Cardiovasc. Dev. Dis., 2023, 10(2): 40[2023-06-25]. . | 
																													
																							| 8 | SILVA GONÇALVES BÓS D D A, VAN DER BRUGGEN C E E, KURAKULA K, et al.. Contribution of impaired parasympathetic activity to right ventricular dysfunction and pulmonary vascular remodeling in pulmonary arterial hypertension[J]. Circulation, 2018, 137(9): 910-924. | 
																													
																							| 9 | CONSTANTINE A, DIMOPOULOS K. Pulmonary artery denervation for pulmonary arterial hypertension[J]. Trends Cardiovasc. Med., 2021, 31(4): 252-260. | 
																													
																							| 10 | ROTHMAN A, JONAS M, CASTEL D, et al.. Pulmonary artery denervation using catheter-based ultrasonic energy[J]. EuroIntervention, 2019, 15(8): 722-730. | 
																													
																							| 11 | MARON B A, LEOPOLD J A. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part Ⅱ: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension[J]. Circulation, 2015, 131(23): 2079-2091. | 
																													
																							| 12 | GARCÍA-LUNAR I, PEREDA D, IBANEZ B, et al.. Neurohormonal modulation as a therapeutic target in pulmonary hypertension[J/OL]. Cells, 2020, 9(11): 2521[2022-01-09]. . | 
																													
																							| 13 | YU W, GU Y, CHEN P, et al.. Norepinephrine stimulation downregulates the β(2)-adrenergic receptor-nitric oxide pathway in human pulmonary artery endothelial cells[J]. J. Cell. Physiol., 2019, 234(2): 1842-1850. |